alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
       
<S>                                        <C>
<PERIOD-TYPE>                              YEAR
<FISCAL-YEAR-END>                          SEP-30-1997
<PERIOD-START>                             OCT-01-1996
<PERIOD-END>                               SEP-30-1997
<CASH>                                         951,945
<SECURITIES>                                 1,023,431
<RECEIVABLES>                                3,344,479
<ALLOWANCES>                                    10,000
<INVENTORY>                                  2,798,903
<CURRENT-ASSETS>                             8,794,230
<PP&E>                                       2,246,371
<DEPRECIATION>                                 954,472
<TOTAL-ASSETS>                              11,144,626
<CURRENT-LIABILITIES>                          990,265
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     5,208,201
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                11,144,626
<SALES>                                      9,292,637
<TOTAL-REVENUES>                             9,292,637
<CGS>                                        4,086,026
<TOTAL-COSTS>                                6,969,170
<OTHER-EXPENSES>                             2,458,923
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                897,430
<INCOME-TAX>                                   312,000
<INCOME-CONTINUING>                            585,430
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   585,430
<EPS-PRIMARY>                                      .12
<EPS-DILUTED>                                        0
        

</TABLE>
[Federal Register Volume 80, Number 51 (Tuesday, March 17, 2015)]
[Notices]
[Page 13863]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-05971]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Heart, Lung, and Blood Institute 
Special Emphasis Panel; Technologies to Assess Sleep Health Status 
in Populations.
    Date: April 10, 2015.
    Time: 2:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Suite 7182, Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Susan Wohler Sunnarborg, Ph.D., Scientific 
Review Officer, Office of Scientific Review/DERA National, Heart, 
Lung, and Blood Institute, 6701 Rockledge Drive, Room 7182, 
Bethesda, MD 20892, <a href="/cdn-cgi/l/email-protection#a7d4d2c9c9c6d5c5c8d5c0d4d0e7c9cfcbc5ce89c9cecf89c0c8d1"><span class="__cf_email__" data-cfemail="9deee8f3f3fceffff2effaeeeaddf3f5f1fff4b3f3f4f5b3faf2eb">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: March 11, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-05971 Filed 3-16-15; 8:45 am]
 BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Exhibit 31.2

CERTIFICATIONS

I, Kurt L. Kalbfleisch, certify that:



|1. | I have reviewed this annual report on Form 10-K/A of Overland Storage, Inc.;
|-- | ----------------------------------------------------------------------------



|2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Date: October 7, 2009



|                                                     
|-----------------------------------------------------
|/s/    KURT L. KALBFLEISCH                           
|Kurt L. Kalbfleisch,                                 
|Vice President of Finance and Chief Financial Officer
|(Principal Financial Officer)
<TABLE> <S> <C>


<ARTICLE> 5
       
<S>                                        <C>
<PERIOD-TYPE>                              9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                       1,948,756
<SECURITIES>                                         0
<RECEIVABLES>                                  181,996
<ALLOWANCES>                                         0
<INVENTORY>                                      9,619
<CURRENT-ASSETS>                             2,140,371
<PP&E>                                       2,443,418
<DEPRECIATION>                               (797,781)
<TOTAL-ASSETS>                               3,786,008
<CURRENT-LIABILITIES>                          200,809
<BONDS>                                        205,383
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        33,576
<OTHER-SE>                                   3,346,240
<TOTAL-LIABILITY-AND-EQUITY>                 3,786,008
<SALES>                                        631,387
<TOTAL-REVENUES>                               944,625
<CGS>                                          212,685
<TOTAL-COSTS>                                  403,406
<OTHER-EXPENSES>                               437,822
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                103,397
<INCOME-TAX>                                  (39,290)
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    64,107
<EPS-PRIMARY>                                      .02
<EPS-DILUTED>                                        0
        



</TABLE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Centers for Disease Control and Prevention

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to (FOA) DP15-009, Improving Surveillance and Prevention of Epilepsy Burden in U.S. Communities.

Time and Date: 10:00 a.m.—6:00 p.m., March 31, 2015 (Closed).

*Place:*                         Teleconference.                    

*Status:*                         The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.                    

*Matters for Discussion:*                         The meeting will include the initial review, discussion, and evaluation of applications received in response to “Improving Surveillance and Prevention of Epilepsy Burden in US Communities”, DP15-009.                    

*Contact Person for More Information:*                         M. Chris Langub, Ph.D., Scientific Review Officer, CDC, 4770 Buford Highway, NE., Mailstop F-80, Atlanta, Georgia 30341, Telephone: (770) 488-3585,                         *EEO6@cdc.gov.*

                        The Director, Management Analysis and Services Office, has been delegated the authority to sign                         **Federal Register**                         notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and                               ( print page 13013)                            Prevention and the Agency for Toxic Substances and Disease Registry.                    

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2015-05576 Filed 3-11-15; 8:45 am]

 BILLING CODE 4163-18-P
EXHIBIT 21.1

                     SUBSIDIARIES OF HENLEY HEALTHCARE, INC.

The following is a list of all of the domestic subsidiaries of the Company as of
December 31, 1999:

                                                                   PERCENTAGE
              DOMESTIC SUBSIDIARIES      STATE OF INCORPORATION    OWNERSHIP
              ---------------------      ----------------------    ----------
Garvey Company...........................        Minnesota             100%
Health Career Learning Systems, Inc. ....         Michigan             100%
Henley Acquisition Corp..................          Texas               100%
Med-Quip, Inc............................         Georgia              100%
NCI, Inc.................................         Michigan             100%

The following is a list of all of the foreign subsidiaries of the Company as of
December 31, 1999:

                                              JURISDICTION          PERCENTAGE
             FOREIGN SUBSIDIARIES           OF INCORPORATION        OWNERSHIP
             --------------------           ---------------------   ----------
Enraf-Nonius, B.V........................    The Netherlands             100%
Enraf-Nonius Medizinelektronik GMBH......       Germany                  100%
Enraf-Nonius Medical Equipment Co. Ltd...       Thailand                  40%
Stats Doyer Hydrotherapie S. A...........        France                   25%
Enraf-Nonius S.A.France..................        France                 99.7%
~· EEF ID:A5·4· 

• 

·-

' 11 

HEADQUARTERS 

ARMY SECURIT-Y AGENCY 

WASHINGTON 21, D. C. 

CSGAS-23 072 14 Jul.11949 

MEM<EANDUM FOR .MR. W. F. FRIEDMAN: 

SUBJE;CT: Invention ot Golt Scoring Device 

1. Reference is made to Memorandum for JS-20 from William F. 

Friedman, dated 1.3 June 1949, subject as above. 

2. The Ar!Q' Security Agency has no interest in the subject device; therefore, notice is hereby given that you are f'ree to prosecute 

the invention at your own ,expense and without obligation to the Govern- . ment. 

JOHN A. GEDDES 

Lt. Colonel, Signal Corps Acting Deputy Chief' 

Army Security Agenay 

@'pproved for Release by NSA on 04-10-2014 pursuant to E.O. 1352e 

- ..,
REF ID:A66583 

ha.n. Balfb A. ~ 

lackhr.11 khaol t4 ~ta ltn:.41• 

t1'n1ve:rai'b tit IC!ehip?t 

Am Atbox', Kl~ 

Illar Dean hvTeri 

----- ---------~ 

n.. ~' • ottico ,_. iatarae4 • \hat JOU V11l 

&ft"'ive at ttae St&tla' Jlotel 1a ~cm fU'ound ten o•cloclt 

ia ~· wtt.f.\1.q on the ttfteerr"11 ot tlU.9 muth1 and that on 

the .uteen.th JOU 4o Mt f1Xj.4d to be mo ~vun 'ten a.n4 

two 0 I eJ.Gc}:,.. 

l will De ft:l";Y h8JW' to me1i J'OU at tU ~B Cl\W 

at tom! 0 'cloek lit. the afternoon ot the •1xteexr.J\ to 

U.®'ta tbe Mtter cm '111\j,ch l tole;phoncd fOU a hv 6a;ya _.," 

A tel.ophono call w • (Llbert7 , ... 67001 ~ion SQl.93) 

on tlle 12'1 u1 :ft<: at thtl •1xt"1rth to eontil'm thit ..-ttnc 

vcul4 \e anncte:t~. 

OCI Al 

C/S 

I/ASST~. PJr1e4mD) ~ 

llleo fw --=~: .. lt-nplena:taey-. 

·~, 

@'pp roved for Release by NSA on 06-19-2014 pursuantto E .0. 1352a
<PAGE>




                                                                    Exhibit 31.2

I, Ron Lipstein, certify that:

1. I have reviewed this amended annual report on Form 10-K of Ortec
International, Inc.;

2. Based on my knowledge, this amended annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this amended
annual report;

3. Based on my knowledge, the financial statements, and other financial
information included in the annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in the annual report;

4. The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material
   information relating to the registrant, including its consolidated
   subsidiaries, is made known to us by others within those entities,
   particularly during the period in which this amended annual report is being
   prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
   procedures as of a date within 90 days prior to the filing date of this
   amended annual report (the "Evaluation Date"); and

c) presented in this amended annual report our conclusions about the
   effectiveness of the disclosure controls and procedures based on our
   evaluation as of the Evaluation Date;

5. The registrant's other certifying officer and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
the registrant's board of directors (or persons performing the equivalent
functions):

a) all significant deficiencies in the design or operation of internal controls
   which could adversely affect the registrant's ability to record, process,
   summarize and report financial data and have identified for the registrant's
   auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other
   employees who have a significant role in the registrant's internal controls;
   and




<PAGE>



6. The registrant's other certifying officer and I have indicated in this
amended annual report whether there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.


Date:  June 23, 2004


                                                 /s/ Ron Lipstein
                                                 ----------------
                                                 RON LIPSTEIN
                                                 Principal Financial Officer
• 

~I • REF ID:A58622 

DEPARTMENT OF DEFENSE 

ARMED FORCES SECURITY AGENCY 

WASHINGTON 25, D. C. 

Jlr. Harold P. !d•mdlon 

4SS3i Wen 18th Street. 

toe Angele• 19, Calitond.a 

Dear Jtr. mlmumlloa: 

• IN REPLY REFER TO 

l3 F•bruazoT 1951 

Thank JOU tor J'01U' lett.er ot S Jebruart and tor the report.. 

which nre incloHd, in part,1.C\llar the pn-publ1catJ.on. copt •f 

the tirat report; on the languap traulation et\ldl'. 

All ,ou auraieed the report, 11 of conalclerabl• 1nte:re•t te 

• ud attar I ban been able to perue the report. more carefllUJ' 

I aball forward to JOll rq comment• on \he poe•ib1llt.iea ot 1\s pract.ical u1e. 

Meanwhile, I wilh JOU woe••• 1n ;pour pre-doctoral work and 

hope tlaat JOU will continue to bring to wr att.eation 1Ueh mathe-

•tical artlclea or J*'oject• u 7011 think _,. 'be ot inte!'eat. to 

-· 

1IILLIAJI r. FRIEDIWI 

@'pp roved for Release by NSA on 04-10-2014 pursuantto E .0. 1352a
1

In the United States Court of Federal Claims

OFFICE OF SPECIAL MASTERS

No. 19-1699V

Filed: April 27, 2021

* * * * * * * * * * * * *

MIR HASSAN, * UNPUBLISHED

*

Petitioner, * Decision on Joint Stipulation;

* Guillain Barre Syndrome

v. * (“GBS”); Influenza (“Flu”)

* Vaccine.

SECRETARY OF HEALTH *

AND HUMAN SERVICES, *

*

Respondent. *

* * * * * * * * * * * * *

Nancy Meyers, Esq., Turning Point Litigation, Greensboro, NC, for petitioner.

Claudia Gangi, Esq., US Department of Justice, Washington, DC, for respondent.

DECISION ON JOINT STIPULATION1

Roth, Special Master:

On October 13, 2019, Mir Hassan [“Mr. Hassan” or “petitioner”] filed a petition for 

compensation under the National Vaccine Injury Compensation Program.

2 Petitioner alleges that 

he suffered from Guillain Barre Syndrome (“GBS”) after receiving an influenza (“flu”) vaccine

on October 12, 2018. Stipulation, filed April 27, 2021, at ¶¶ 1-4. Respondent denies that the

immunization caused petitioner’s injury. Stipulation at ¶ 6.

1 Although this Decision has been formally designated “unpublished,” it will nevertheless be posted on the 

Court of Federal Claims’ website, in accordance with the E-Government Act of 2002, Pub. L. No. 107-347, 

116 Stat. 2899, 2913 (codified as amended at 44 U.S.C. § 3501 note (2006)). This means the Decision will 

be available to anyone with access to the internet. However, the parties may object to the Decision’s 

inclusion of certain kinds of confidential information. Specifically, under Vaccine Rule 18(b), each party 

has fourteen days within which to request redaction “of any information furnished by that party: (1) that is 

a trade secret or commercial or financial in substance and is privileged or confidential; or (2) that includes 

medical files or similar files, the disclosure of which would constitute a clearly unwarranted invasion of 

privacy.” Vaccine Rule 18(b). Otherwise, the whole Decision will be available to the public. Id.

2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease 

of citation, all “§” references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 300aa 

(2012).
2

Nevertheless, the parties have agreed to settle the case. On April 27, 2021, the parties filed 

a joint stipulation agreeing to settle this case and describing the settlement terms.

Respondent agrees to issue the following payment:

A lump sum of $85,000.00 in the form of a check payable to petitioner, Mir 

Hassan. This amount represents compensation for all damages that would be available 

under § 300aa-15(a).

I adopt the parties’ stipulation attached hereto, and award compensation in the amount and 

on the terms set forth therein. The clerk of the court is directed to enter judgment in accordance 

with this decision.3

IT IS SO ORDERED.

s/ Mindy Michaels Roth

Mindy Michaels Roth

Special Master

3 Pursuant to Vaccine Rule 11(a), entry of judgment can be expedited by each party filing a notice 

renouncing the right to seek review.
<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          SEP-30-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                       6,580,000
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             6,580,000
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               6,580,000
<CURRENT-LIABILITIES>                           60,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        48,000
<OTHER-SE>                                   6,472,000
<TOTAL-LIABILITY-AND-EQUITY>                 6,580,000
<SALES>                                              0
<TOTAL-REVENUES>                               531,000
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                               512,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 19,000
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                             19,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    19,000
<EPS-BASIC>                                       0.01
<EPS-DILUTED>                                     0.01



</TABLE>